Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ARQT

Arcutis Biotherapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ARQT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-0.13

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 04:35 UTC.

What Arcutis Biotherapeutics, Inc. does

Arcus Biosciences is a commercial-stage biopharmaceutical company developing treatments for dermatological diseases with high unmet medical needs. The company's lead product, ZORYVE, is a topical formulation of roflumilast, a phosphodiesterase-4 inhibitor available in cream and foam forms that has received FDA approval for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis across various age groups. ZORYVE has been launched in the United States and Canada, with the company pursuing additional indications including treatment in younger children and infants.

Summarized from Arcutis Biotherapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2025)$-0.13
Debt/equity0.49

Revenue, margins & earnings

FY2022: net loss $311M on revenue $4M$4MFY2022FY2023: net loss $262M on revenue $60M$60MFY2023FY2024: net loss $140M on revenue $197M$197MFY2024FY2025: net loss $16M on revenue $376M$376MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-18
  • 2026-09-18See RemarksSale-3,674$91.9K
  • 2026-09-17DirectorStock Option (right to buy)Option exercise-2,255—
  • 2026-09-17DirectorOption exercise2,255$19.5K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Arcutis Biotherapeutics, Inc. do?

Arcus Biosciences is a commercial-stage biopharmaceutical company developing treatments for dermatological diseases with high unmet medical needs.

When did ARQT last file with the SEC?

Arcutis Biotherapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-09. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 04:35 UTC. This page is also available as JSON at /api/data?ticker=ARQT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ARQT and 5,000+ tickers.

Create a free account — keep ARQT
For your agent
GET /api/data?ticker=ARQT

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt